Reuters logo
BRIEF-Eli Lilly says additional results from pivotal ra-beam study published in New England Journal of Medicine
February 15, 2017 / 11:08 PM / 7 months ago

BRIEF-Eli Lilly says additional results from pivotal ra-beam study published in New England Journal of Medicine

Feb 15 (Reuters) - Eli Lilly

* Eli Lilly - additional results from pivotal ra-beam study published in New England Journal of Medicine

* Eli Lilly - results show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo

* Eli Lilly- through 52-week period, serious adverse event rates were 8 percent for baricitinib and 4 percent for adalimumab

* Eli Lilly - total of 5 deaths were reported in study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below